

**Amendments to the Claims:**

The following Listing of the Claims replaces all prior versions and all prior listings of the claims in the present application:

Listing of the Claims

1-65. (Cancelled herein)

66. (New) A method of activating NFκB activity in a mammal afflicted with an autoimmune disease in which a reduction in NFκB activity is observed, comprising administering to a mammal suffering from said autoimmune disease a therapeutically effective amount of a polypeptide which activates NFκB, so as to reduce the symptoms of said autoimmune disease.

67. (New) The method of claim 66 wherein said polypeptide is selected from the group consisting of NFκB, NFκB p50, NFκB p52, NFκB p65, IκB, IL-1 and TNF-α.

68. (New) The method of claim 66 wherein said polypeptide comprises an antibody.

69. (New) The method of claim 66 wherein said polypeptide activates NFκB in a cell in said mammal.

70. (New) The method of claim 66 wherein said mammal is a human.

71. (New) A method of reducing the symptoms of an autoimmune disease in which a reduction in NFκB activity is observed, comprising administering to a mammal suffering from said autoimmune disease a therapeutically effective amount of a polypeptide which activates NFκB, so as to reduce the symptoms of said autoimmune disease in said mammal.

72. (New) The method of claim 71 wherein said polypeptide is selected from the group consisting of NFκB, NFκB p50, NFκB p52, NFκB p65, IκB, IL-1 and TNF-α.

73. (New) The method of claim 71 wherein said polypeptide comprises an antibody.

74. (New) The method of claim 71 wherein said polypeptide activates NFκB in a cell in said mammal.

Docket No.: 17633/1124

75. (New) The method of claim 71 wherein said mammal is a human.